203 related articles for article (PubMed ID: 27811606)
1. Platinum Compound-Related Ototoxicity in Children: Long-Term Follow-Up Reveals Continuous Worsening of Hearing Loss.
Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-655. PubMed ID: 27811606
[TBL] [Abstract][Full Text] [Related]
2. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
[TBL] [Abstract][Full Text] [Related]
3. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma.
Jehanne M; Lumbroso-Le Rouic L; Savignoni A; Aerts I; Mercier G; Bours D; Desjardins L; Doz F
Pediatr Blood Cancer; 2009 May; 52(5):637-43. PubMed ID: 19148943
[TBL] [Abstract][Full Text] [Related]
4. Incidence and associated risk factors for platinum-induced ototoxicity in pediatric patients.
Waissbluth S; Del Valle Á; Chuang A; Becker A
Int J Pediatr Otorhinolaryngol; 2018 Aug; 111():174-179. PubMed ID: 29958605
[TBL] [Abstract][Full Text] [Related]
5. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
[TBL] [Abstract][Full Text] [Related]
6. Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors.
Clemens E; de Vries AC; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; Pluijm SF; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; Neggers SJ; van Grotel M; M van den Heuvel-Eibrink M
Pediatr Hematol Oncol; 2017 Mar; 34(2):120-129. PubMed ID: 28590156
[TBL] [Abstract][Full Text] [Related]
7. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study.
Clemens E; de Vries AC; Pluijm SF; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; van Grotel M; van den Heuvel-Eibrink MM;
Eur J Cancer; 2016 Dec; 69():77-85. PubMed ID: 27821322
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of cisplatin- and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients.
Nitz A; Kontopantelis E; Bielack S; Koscielniak E; Klingebiel T; Langer T; Paulides M
Oncol Lett; 2013 Jan; 5(1):311-315. PubMed ID: 23255940
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma.
Musial-Bright L; Fengler R; Henze G; Hernáiz Driever P
Childs Nerv Syst; 2011 Mar; 27(3):407-13. PubMed ID: 20931205
[TBL] [Abstract][Full Text] [Related]
10. Long-term auditory follow-up in the management of pediatric platinum-induced ototoxicity.
Fetoni AR; Brigato F; De Corso E; Lucidi D; Sergi B; Scarano E; Galli J; Ruggiero A
Eur Arch Otorhinolaryngol; 2022 Oct; 279(10):4677-4686. PubMed ID: 35024956
[TBL] [Abstract][Full Text] [Related]
11. Long-term audiologic follow-up of carboplatin-treated children with retinoblastoma.
Geurtsen ML; Kors WA; Moll AC; Smits C
Ophthalmic Genet; 2017; 38(1):74-78. PubMed ID: 27050825
[TBL] [Abstract][Full Text] [Related]
12. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
Peleva E; Emami N; Alzahrani M; Bezdjian A; Gurberg J; Carret AS; Daniel SJ
Pediatr Blood Cancer; 2014 Nov; 61(11):2012-7. PubMed ID: 24976616
[TBL] [Abstract][Full Text] [Related]
13. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
14. The incidence of hearing impairment after successful treatment of neuroblastoma.
Simon T; Hero B; Dupuis W; Selle B; Berthold F
Klin Padiatr; 2002; 214(4):149-52. PubMed ID: 12165893
[TBL] [Abstract][Full Text] [Related]
15. Audiological Monitoring in Children Treated with Platinum Chemotherapy.
Fetoni AR; Ruggiero A; Lucidi D; De Corso E; Sergi B; Conti G; Paludetti G
Audiol Neurootol; 2016; 21(4):203-211. PubMed ID: 27286730
[TBL] [Abstract][Full Text] [Related]
16. [The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy].
Schmidt CM; Bartholomäus E; Deuster D; Heinecke A; Dinnesen AG
HNO; 2007 Apr; 55(4):299-306. PubMed ID: 16437215
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin ototoxicity in children: a practical grading system.
Brock PR; Bellman SC; Yeomans EC; Pinkerton CR; Pritchard J
Med Pediatr Oncol; 1991; 19(4):295-300. PubMed ID: 2056973
[TBL] [Abstract][Full Text] [Related]
18. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
[TBL] [Abstract][Full Text] [Related]
19. Applications of the Grading Scales for the Detection of Ototoxicity in Children after Treatment of Neuroblastoma and Extracranial Germinal Tumor.
Polski B; Sosnowska-Sienkiewicz P; Szydłowski J; Januszkiewicz-Lewandowska D
Audiol Neurootol; 2023; 28(1):32-42. PubMed ID: 36191558
[TBL] [Abstract][Full Text] [Related]
20. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group.
Landier W; Knight K; Wong FL; Lee J; Thomas O; Kim H; Kreissman SG; Schmidt ML; Chen L; London WB; Gurney JG; Bhatia S
J Clin Oncol; 2014 Feb; 32(6):527-34. PubMed ID: 24419114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
